Duyuru • Mar 27
ClouDr Group Limited, Annual General Meeting, Jun 08, 2026 ClouDr Group Limited, Annual General Meeting, Jun 08, 2026. Duyuru • Mar 16
ClouDr Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026 ClouDr Group Limited announced that they will report fiscal year 2025 results on Mar 26, 2026 Duyuru • Feb 16
ClouDr Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2025 ClouDr Group Limited provided consolidated earnings guidance for the year ended December 31, 2025. Based on the preliminary review of the consolidated management accounts of the Group for the year ended December 31, 2025 (the "Reporting Year"), the Group is expected to record a consolidated net loss ranging between approximately RMB 880 million and approximately RMB 980 million as compared to a consolidated net loss of approximately RMB 491.4 million for the year ended December 31, 2024. Based on the information currently available, the Board considers that the expected increase in loss was mainly due to the strategic transformation of the Group to restructure its business model to prioritise high-quality and cash-generation growth by focusing on the core AI capabilities. This has resulted in significant impairment losses recognized on disposals of certain subsidiaries and a one-off specific provision related to a business whose counterparty is under major lawsuits or judicial investigations. Due to the strategic divestment from businesses of sales of medical supplies with low profit margin and transformation to focus on AI-driven P2M business with higher operating efficiency, the net cash inflow in operating activities of the Group is expected to range between approximately RMB50 million and approximately RMB80 million for the Reporting Year as compared to a net cash outflow in operating activities of approximately RMB148.4 million for the year ended December 31, 2024. Duyuru • Aug 15
ClouDr Group Limited to Report First Half, 2025 Results on Aug 27, 2025 ClouDr Group Limited announced that they will report first half, 2025 results on Aug 27, 2025 Duyuru • Mar 31
ClouDr Group Limited, Annual General Meeting, Jun 11, 2025 ClouDr Group Limited, Annual General Meeting, Jun 11, 2025. Duyuru • Mar 18
ClouDr Group Limited announced that it has received $4.5 million in funding from Global Connectivity Group Limited, Hygge Life Co. Limited and other investors On March 17, 2025, ClouDr Group Limited closed the transaction. Duyuru • Mar 14
ClouDr Group Limited to Report Fiscal Year 2024 Results on Mar 26, 2025 ClouDr Group Limited announced that they will report fiscal year 2024 results on Mar 26, 2025 Duyuru • Mar 11
ClouDr Group Limited announced that it expects to receive $4.5 million in funding from Global Connectivity Group Limited, Hygge Life Limited and other investors ClouDr Group Limited announced that it has entered into the Subscription Agreement with the Subscribers and the Sole Placing Agent in relation to the issue of Convertible Bonds in an aggregate principal amount of $4,500,000 on March 10, 2025. The bonds are Upon full conversion of the Convertible Bonds at the initial Conversion Price of HKD 2.10($0.27025) per Conversion Share a total of 16,645,500 Conversion Shares will be issued, representing approximately 2.58% of the existing issued share capital of the Company and approximately 2.51% of the issued share capital of the Company as enlarged by the issue of the Conversion Shares. The Conversion Shares will be allotted and issued pursuant to the General Mandate. The transaction will include participation from Subscriber A Hygge Life Co. Limited $2,000,000, Subscriber B Foresee International Fund SPC — Foresee International Fund Conservative SP $1,500,000, Subscriber C Global Connectivity Group Limited $500,000 and Subscriber D HU Yue $500,000. The bonds matures in the second anniversary of the issue date of the Convertible Bonds.On Maturity Date: Unless previously redeemed, converted, purchased or cancelled, the Company will redeem the Convertible Bonds at the Applicable Redemption Amount. The Convertible Bonds constitute direct, unsecured, unsubordinated and unconditional obligations of the Company and shall at all times rank pari passu and without any preference or priority among themselves. The transaction is expected to close on March 17, 2025, or such other time as the Company and the Subscribers may agree after the fulfilment of the conditions precedent. Duyuru • Dec 04
ClouDr Group Limited Appoints Zuo Yinghui as Executive Director The board of directors of ClouDr Group Limited announced that, with effect from December 4, 2024, Ms. Zuo Yinghui (Ms. Zuo) has been appointed as an executive Director of the Company. Biographical details of Ms. Zuo are set out below: Ms. Zuo Yinghui, aged 48, has served as the vice president of the Company since January 2015, primarily responsible for supply chain management and business development. Ms. Zuo is also a supervisor of (91health Shanghai Limited, a subsidiary of the Company) and a director of (Tianjin Hexi District Youyi Xinhe General Outpatient Co. Ltd., a subsidiary of the Company). Prior to joining the Group, Ms. Zuo held various positions at Johnson & Johnson (Shanghai) Medical Equipment Co. Ltd, a subsidiary of Johnson & Johnson (a company currently listed on the New York Stock Exchange from October 1999 to December 2014, with her last role serving as the senior sales operation manager. Ms. Zuo received a bachelor's degree in English from Shanghai University in PRC in 1997. New Risk • Oct 30
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €89.3m (US$96.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (CN¥23m net loss next year). Market cap is less than US$100m (€89.3m market cap, or US$96.7m). New Risk • Oct 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable next year (CN¥23m net loss next year). Reported Earnings • Sep 27
First half 2024 earnings released: CN¥0.20 loss per share (vs CN¥0.29 loss in 1H 2023) First half 2024 results: CN¥0.20 loss per share (improved from CN¥0.29 loss in 1H 2023). Revenue: CN¥2.12b (up 18% from 1H 2023). Net loss: CN¥115.8m (loss narrowed 26% from 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Healthcare industry in Germany. New Risk • Aug 28
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €88.6m (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (CN¥23m net loss next year). Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (€88.6m market cap, or US$98.6m). Reported Earnings • Aug 26
First half 2024 earnings released: CN¥0.20 loss per share (vs CN¥0.29 loss in 1H 2023) First half 2024 results: CN¥0.20 loss per share (improved from CN¥0.29 loss in 1H 2023). Revenue: CN¥2.12b (up 18% from 1H 2023). Net loss: CN¥115.8m (loss narrowed 26% from 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. New Risk • Aug 22
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CN¥283m Forecast net loss in 1 year: CN¥3.7m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (CN¥3.7m net loss next year). Share price has been volatile over the past 3 months (8.7% average weekly change). Duyuru • Aug 09
ClouDr Group Limited to Report First Half, 2024 Results on Aug 21, 2024 ClouDr Group Limited announced that they will report first half, 2024 results on Aug 21, 2024 Duyuru • Jun 08
ClouDr Group Limited Announces Resignation of Director and Change in Composition of Audit Committee ClouDr Group Limited announced Mr. Lee Kar Chung Felix has informed the Company that due to his other work commitment which requires more of his time and dedication, Mr. Lee shall resign as a non-executive Director with effect from the conclusion of the AGM. Mr. Lee has therefore resigned as a Director and is no longer a member of the Audit Committee with effect from the conclusion of the AGM. Mr. Lee has confirmed that he The Board further announces that following Mr. Lee's resignation and Mr. Ang Khai Meng's re-election as an independent non-executive Director at the AGM, Mr. Ang has been appointed as a member of the Audit Committee from the conclusion of the AGM. Duyuru • Jun 06
ClouDr Group Limited Announces Application for Market Launch of Vitamin B6 Injection Solution The board of directors of ClouDr Group Limited announced that the application for market launch of Vitamin B6 injection solution developed by Polifarma (Nanjing) Pharmaceutical Company Limited. The Vitamin B6 Injection Solution subject to the application by Nanjing Polifarma is the first batch of Vitamin B6 product subject to consensus evaluation in China, which reflects the stringent control over raw materials of Nanjing Polifarma and the level of advancement of its production process. The Vitamin B6 Injection Solution subject to the application by Nanjing Polifarma is the first batch of Vitamin B6 product subject to consensus evaluation in China, which reflects the stringent control over raw materials of Nanjing Polifarma and the level of advancement of its production process. As of December 31, 2023, there were 66 enterprises in China selling Vitamin B6 injection solutions with approximately 570 million packs on the market. However, none of the products currently on the market has passed the consensus evaluation. The Group's product subject to the application has passed the consensus evaluation. According to relevant government policy, such products will be prioritized in the selection of clinical applications. It is expected that this would contribute to a sizeable potential market for the Vitamin B6 Injection Solution of Nanjing Polifarma in the future. Meanwhile, once the product has passed the consensus evaluation, the pharmaceutical and bioequivalence will deliver higher level of assurance. Therefore, the launch of the Vitamin B6 Injection Solution of Nanjing Polifarma will also improve the patient accessibility of quality drugs. The Board considers that the application of market launch of the Vitamin B6 Injection Solution, when approved, will mark this product as another key product of Nanjing Polifarma. The Group will carry out marketing and sales activities for the Vitamin B6 Injection Solution upon its launch to the market, leveraging the Group's own extensive hospital and pharmacy channels and digitization capability, which will be beneficial to the long term development of the Group and is in the interests of the Company and its shareholders as a whole. Reported Earnings • Mar 24
Full year 2023 earnings released: CN¥0.60 loss per share (vs CN¥5.62 loss in FY 2022) Full year 2023 results: CN¥0.60 loss per share (improved from CN¥5.62 loss in FY 2022). Revenue: CN¥3.69b (up 24% from FY 2022). Net loss: CN¥323.1m (loss narrowed 81% from FY 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Duyuru • Mar 23
ClouDr Group Limited, Annual General Meeting, Jun 06, 2024 ClouDr Group Limited, Annual General Meeting, Jun 06, 2024. New Risk • Mar 23
New major risk - Revenue and earnings growth Earnings have declined by 10% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 10% per year over the past 5 years. Board Change • Jan 30
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Founder, Chairman & CEO Ming Kuang is the most experienced director on the board, commencing their role in 2015. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Duyuru • Dec 19
Cloudr Group Limited Announces Resignation of Liu Mengya as Joint Company Secretary ClouDr Group Limited announced that Ms. Liu Mengya ("Ms. Liu") has tendered her resignation as a joint company secretary of the Company with effect from December 19, 2023. Ms. Liu confirmed that she has no disagreement with the Board and there are no matters in relation to her resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the "Stock Exchange"). Duyuru • Nov 17
ClouDr Group Limited Announces New Efficacy of Ischelium on Brain Covidative Fund Approval The board of directors of ClouDr Group Limited announced that Dr. Liu Hongying, the chief medical officer of the Company, has led a team in the researches in collaboration with Chinese national key institutes of scientific research on the efficacy of a self-owned and developed medicine of the Group, Ischelium (Dihydroergotoxine Methanesulfonate), on improving cognitive function. The latest research findings were accepted by "Biochemical and Biophysical Research Communications", an international renowned academic journal. Such fundamental research explored the intervention effect and potential mechanism of Ischelium®? regarding declining cognitive function in an in-depth manner. As stated in the research, Ischelium®? enhanced antioxidant enzyme activities in the hippocampus of laboratory animals, regulated Nrf2/HO-1 signaling pathway and reduced the production of pro-inflammatory cytokines IL-1b and TNF-a in the hippocampus. This resulted in decreased expression of factors related to cognitive function, which in turn produced neuroprotective effects. Meanwhile, the research found that Ischelium®? can significantly improve laboratory animals' cognitive, learning and memory functions by protecting the neurons in the hippocampus. These findings have provided scientific basis for the potential of Ischelium®? in slowing down aging, treating aging related diseases and improving the health of the elderly. The Group's self-owned and developed medicine Ischelium® (Guoyaozhunzi H20093234) has been approved in the PRC for years. Its mechanism of action is comprehensive and there is a wide range of potential target patients. With its extensive clinical applications, it has been widely recognized by clinical doctors in respect of mild vascular dementia and cerebrovascular disease. Ischelium® is an equal-proportion mixture of four dihydro derivatives of natural ergot alkaloids. The clinical research indicated that Ischelium® significantly improved the drooling symptom in patients with Parkinson's disease and it was recommended by "Consensus on the clinical management of gastrointestinal symptoms of patients with Parkinson's disease in China" in 2022, which further expanded the application of Ischelium® on aging related neurodegenerative disorder. Cognitive impairment is considered to be the transitional phase between normal aging and Alzheimer's disease ("AD"). AD is an age related progressive neurodegenerative disorder with impaired cognitive function as its key clinical presentation. It may be caused by a combination of various factors such as genetic factors, environmental factors and bodily factors. This study provides further evidence that Ischelium® can significantly improve cognitive, learning and memory functions of aging animals and its potential mechanism of action, indicating its potential application regarding aging related diseases. The Company has always been adhering to a patient-centered approach, focusing on digital chronic disease management, and at the same time, continuously exploring the frontiers of scientific research and service model innovation in chronic disease management, in order to contribute more to the health care of patients with chronic diseases. The Company has also initiated research on the prevention and treatment of AD and is looking forward to achieving more fruitful results in the future for the benefit of AD patients. Recent Insider Transactions • Oct 31
Founder recently bought €91k worth of stock On the 27th of October, Ming Kuang bought around 116k shares on-market at roughly €0.79 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Ming has been a buyer over the last 12 months, purchasing a net total of €159k worth in shares. Reported Earnings • Sep 26
First half 2023 earnings released: CN¥0.29 loss per share (vs CN¥11.94 loss in 1H 2022) First half 2023 results: CN¥0.29 loss per share (improved from CN¥11.94 loss in 1H 2022). Revenue: CN¥1.80b (up 31% from 1H 2022). Net loss: CN¥156.0m (loss narrowed 87% from 1H 2022). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Breakeven Date Change • Sep 01
Forecast to breakeven in 2025 The 4 analysts covering ClouDr Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 75% per year to 2024. The company is expected to make a profit of CN¥172.6m in 2025. Average annual earnings growth of 98% is required to achieve expected profit on schedule. Board Change • Sep 01
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Founder, Chairman & CEO Ming Kuang is the most experienced director on the board, commencing their role in 2015. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 20
First half 2023 earnings released: CN¥0.29 loss per share (vs CN¥11.94 loss in 1H 2022) First half 2023 results: CN¥0.29 loss per share (improved from CN¥11.94 loss in 1H 2022). Revenue: CN¥1.80b (up 31% from 1H 2022). Net loss: CN¥156.0m (loss narrowed 87% from 1H 2022). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Duyuru • Aug 09
ClouDr Group Limited to Report First Half, 2023 Results on Aug 18, 2023 ClouDr Group Limited announced that they will report first half, 2023 results on Aug 18, 2023 Board Change • Jul 26
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Founder, Chairman & CEO Ming Kuang is the most experienced director on the board, commencing their role in 2015. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. 
